Global Anti-Diabetic Drugs Market Growth (Status and Outlook) 2023-2029

Global Anti-Diabetic Drugs Market Growth (Status and Outlook) 2023-2029

The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.

LPI (LP Information)' newest research report, the “Anti-Diabetic Drugs Industry Forecast” looks at past sales and reviews total world Anti-Diabetic Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti-Diabetic Drugs sales for 2023 through 2029. With Anti-Diabetic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Diabetic Drugs industry.

This Insight Report provides a comprehensive analysis of the global Anti-Diabetic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-Diabetic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-Diabetic Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Diabetic Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Diabetic Drugs.

The global Anti-Diabetic Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II. 

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Diabetic Drugs market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Biguanides
Sulfonylureas
Meglitinides
Thiazolidinediones
Dipeptidyl Peptidase IV Inhibitors
α-Glucosidase Inhibitors

Segmentation by application
Type I Diabetes
Type II Diabetes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Astra Zeneca
Boehringer Ingelheim
Eli Lilly
Johnson & Johnson
Merck
Novartis
Novo Nordisk
Sanofi
Teva Pharmaceutical Industries

Please note: The report will take approximately 2 business days to prepare and deliver.